- Home
- SKYH vs FBRX Comparison
SKYH vs FBRX Comparison
Compare SKYH & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYH | FBRX |
|---|---|---|
| Founded | 2017 | N/A |
| Country | | |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.6M | 367.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SKYH | FBRX |
|---|---|---|
| Price | $8.88 | $30.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $13.83 | ★ $67.00 |
| AVG Volume (30 Days) | 130.1K | ★ 244.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $95.36 | N/A |
| Revenue Next Year | $69.38 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.22 | $4.90 |
| 52 Week High | $14.20 | $35.62 |
Technical Indicators
Market Signals| Indicator | SKYH | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.50 | 50.83 |
| Support Level | $8.28 | $27.88 |
| Resistance Level | $9.42 | $31.19 |
| Average True Range (ATR) | 0.38 | 3.67 |
| MACD | -0.05 | -0.36 |
| Stochastic Oscillator | 46.40 | 40.33 |
Price Performance
Historical ComparisonAbout SKYH Sky Harbour Group Corporation
Sky Harbour Group Corp is an aviation infrastructure company building a nationwide network of Home-based solutions for business aircraft. The company develops, leases, and manages business aviation hangars across the United States based on its proprietary targeting and acquisition model, targeting airfields with hangar supply and demand imbalances in the markets. Its hangar campuses feature exclusive private hangars and a full suite of dedicated services specifically designed for home-based aircraft.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).